1. Home
  2. GENK vs IMRN Comparison

GENK vs IMRN Comparison

Compare GENK & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GEN Restaurant Group Inc.

GENK

GEN Restaurant Group Inc.

N/A

Current Price

$1.52

Market Cap

9.1M

ML Signal

N/A

Logo Immuron Limited

IMRN

Immuron Limited

N/A

Current Price

$0.95

Market Cap

7.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GENK
IMRN
Founded
2011
1994
Country
United States
Australia
Employees
2700
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
7.7M
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
GENK
IMRN
Price
$1.52
$0.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 2.1M
35.0K
Earning Date
11-10-2026
08-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 62.50
N/A
EPS
N/A
★ N/A
Revenue
★ $208,380,000.00
N/A
Revenue This Year
$2.05
$16.39
Revenue Next Year
$4.93
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 15.12
N/A
52 Week Low
$1.39
$0.68
52 Week High
$3.12
$2.18

Technical Indicators

Market Signals
Indicator
GENK
IMRN
Relative Strength Index (RSI) 44.20 35.48
Support Level $1.53 $0.94
Resistance Level $2.25 $1.00
Average True Range (ATR) 0.18 0.07
MACD -0.00 -0.00
Stochastic Oscillator 14.41 15.45

Price Performance

Historical Comparison
GENK
IMRN

About GENK GEN Restaurant Group Inc.

GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.

About IMRN Immuron Limited

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

Share on Social Networks: